Delving into the Latest Updates on Rimantadine Hydrochloride with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

Rimantadine, Rimantadine Hydrochloride Granules, Rimantadine Hydrochloride Syrup

+ [13]

Target

M2 protein

Action

inhibitors

Mechanism

M2 protein inhibitors(Matrix protein 2 inhibitors)

Therapeutic Areas

Infectious DiseasesRespiratory Diseases

Active Indication

Influenza A virus infection

Inactive Indication-

Originator Organization

Sun Pharmaceutical Industries Ltd.

Active Organization

Apeloa Pharmaceutical Co., Ltd.

Inactive Organization

Sun Pharmaceutical Industries, Inc.Forest Laboratories, Inc.

License Organization-

Drug Highest PhaseApproved

First Approval Date

United States (17 Sep 1993),

Influenza A virus infection

Regulation-

Login to view timeline

Structure/Sequence

Molecular FormulaC12H21N

InChIKeyUBCHPRBFMUDMNC-UHFFFAOYSA-N

CAS Registry13392-28-4

View All Structures (2)

Hepatitis C virus is one of the leading causes of liver failure and liver cancer worldwide. Current treatment of hepatitis C infection is only successful in about half of those who are eligible. The current treatment aims to boost the host immune system but does not directly act on the virus. Many drugs are in various stages of development that target the virus directly - their specific mode of action is confirmed by showing the virus is forced to adapt in the presence of the drug. As with many viruses, treating with only one specific drug would quickly lead to the virus adapting and becoming resistant. We therefore need to find new combinations of directly acting drugs. Rimantadine has already been shown in the laboratory to target hepatitis C directly. We have designed this study to see if it happens in real life as well. If so, we could use rimantadine to help fight hepatitis c more effectively.

Start Date01 May 2012

Sponsor / Collaborator

Leeds Teaching Hospitals NHS Trust

[+1]

NCT01172847

/ CompletedPhase 1

An Open-label, Multiple Dose, Randomized, Three-period Crossover Study in Healthy Subjects to Evaluate the Effect of Co-administration of Oseltamivir (Ro 64-0796) 75 mg Twice Daily and Rimantadine 100 mg Twice Daily on the Pharmacokinetic Properties of Oseltamivir and Rimantadine.

This open label, randomized, three-period crossover study will evaluate the effect of co-administration of Tamiflu (oseltamivir) and rimantadine on the pharmacokinetics of Tamiflu and rimantadine. Healthy volunteers will receive multiple oral doses of Tamiflu, rimantadine or Tamiflu plus rimantadine in random order, with a minimum wash-out period of 7 days between treatments. Anticipated time on study is up to 11 weeks.

Start Date01 Aug 2009

Sponsor / Collaborator

Hoffmann-La Roche, Inc.

100 Clinical Results associated with Rimantadine Hydrochloride

Login to view more data

100 Translational Medicine associated with Rimantadine Hydrochloride

Login to view more data

100 Patents (Medical) associated with Rimantadine Hydrochloride

Login to view more data

1,676

Literatures (Medical) associated with Rimantadine Hydrochloride

01 Jun 2025·Colloids and Surfaces B: Biointerfaces

Revealing the mechanism of two rimantadine derivatives inhibiting Aβ aggregation and destabilizing Aβ protofibrils by molecular dynamics simulation

Article

Author: Qi, Wei ; Zhang, Chengyu ; Wang, Yuefei ; Su, Rongxin ; Yang, Yufan ; Zhang, Jiaxing

Two rimantadine derivatives, m-aminobenzoyl rimantadine (meta) and p-aminobenzoyl rimantadine (para), have been demonstrated to effectively inhibit the aggregation of amyloid-β (Aβ) peptides. However, the exact atomic-level mechanism remains elusive. In this study, we investigated the inhibitory mechanisms of meta and para on Aβ aggregation. Using replica-exchange and microsecond classical molecular dynamics simulations, we analyzed the conformational ensembles of Aβ dimers and the structure of Aβ(1-40) protofibrils both with and without the rimantadine derivatives. Results showed that meta and para inhibit Aβ aggregation by hydrogen bonds and hydrophobic interactions with Aβ dimers. Meta mainly binds to CHC residues F19 and F20 to disrupt hydrophobic contacts, while para targets β-turns and the K28-V40 region, destabilizing the hydrophobic core and increasing structural flexibility, thus preventing stable dimer formation. Para exhibits a higher binding affinity and is more effective in inhibiting Aβ aggregation and destabilizing protofibrils. These findings provide valuable insights into the atomic-level mechanisms by which meta and para inhibit Aβ aggregation, offering promising avenues for the exploration of potential therapeutics for Alzheimer's disease (AD).

01 Apr 2025·Antiviral Research

Antiviral mechanisms and preclinical evaluation of amantadine analogs that continue to inhibit influenza A viruses with M2S31N-based drug resistance

Article

Author: Kwan, Daniel C ; Antoniadou, Ivi Theodosia ; Tzitzoglaki, Christina ; Johnson, F Brent ; Sureda, Francesc X ; Fedida, David ; Rallis, Michail ; Tietjen, Ian ; Petrich, Annett ; Mestdagh, Cato ; Chiantia, Salvatore ; Zell, Roland ; Kolocouris, Antonios ; Naesens, Lieve ; Gavriilidou, Agni

To better manage seasonal and pandemic influenza infections, new drugs are needed with enhanced activity against amantadine- and rimantadine-resistant influenza A virus (IAV) strains containing the S31N variant of the viral M2 ion channel (M2^S31N). Here we tested 36 amantadine analogs against a panel of viruses containing either M2^S31N or the parental, M2 S31 wild-type variant (M2^WT). We found that several analogs, primarily those with sizeable lipophilic adducts, inhibited up to three M2^S31N-containing viruses with activities at least 5-fold lower than rimantadine, without inhibiting M2^S31N proton currents or modulating endosomal pH. While M2^WT viruses in passaging studies rapidly gained resistance to these analogs through the established M2 mutations V27A and/or A30T, resistance development was markedly slower for M2^S31N viruses and did not associate with additional M2 mutations. Instead, a subset of analogs, exemplified by 2-propyl-2-adamantanamine (38), but not 2-(1-adamantyl)piperidine (26), spiro[adamantane-2,2'-pyrrolidine] (49), or spiro[adamantane-2,2'-piperidine] (60), inhibited cellular entry of infectious IAV following pre-treatment and/or H1N1 pseudovirus entry. Conversely, an overlapping subset of the most lipophilic analogs including compounds 26, 49, 60, and others, disrupted viral M2-M1 protein colocalization required for intracellular viral assembly and budding. Finally, a pilot toxicity study in mice demonstrated that 38 and 49 were tolerated at 30 mg/kg. Together, these results indicate that amantadine analogs act on multiple, complementary mechanisms to inhibit replication of M2^S31N viruses.

24 Mar 2025·Journal of Biomolecular Structure and Dynamics

Inhibition of respiratory syncytial virus by Daclatasvir and its derivatives: synthesis of computational derivatives as a new drug development

Article

Author: Afreen, Shagufta ; Mitra, Debanjan ; Das Mohapatra, Pradeep K. ; Abdalla, Mohnad

The most common cause of respiratory tract illness in newborns and young children is the respiratory syncytial virus (RSV). There is no approved vaccination or specific antiviral medication for RSV infections. Here, an attempt has been made to explore the potential of currently marketed drugs as well as their probable derivatives to improve the possibility of developing stronger medications against RSV. From the 100 synthetic drug compounds library, the best drug molecule was identified through drug-likeness properties, toxicity, molecular docking and molecular dynamics simulations. Molecular Mechanics Generalized Born Surface Area (MM-GBSA) was also a method that was applied in this study. Daclatasvir showed the highest binding energy and appeared as the best drug to inhibit matrix protein and a fusion protein of RSV. Based on Daclatasvir, 40 computational derivatives were made. D28, D34 and D40 showed far better results than the actual drug. Changes in lipophilicity character increase the binding energy of derivatives. Molecular dynamic simulations showed their non-deviated, non-fluctuated and stable complex formation with target proteins. The high number of amino acid contacts throughout the trajectory increases the stability and effectiveness of derivatives. The key to producing a novel medicine to eradicate RSV is provided by derivatives. Daclatasvir will be employed as a potential RSV inhibitor up until that point.

100 Deals associated with Rimantadine Hydrochloride

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D00901	Rimantadine Hydrochloride	J05AC02	DB00478

R&D Status

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Influenza A virus infection	China	Apeloa Pharmaceutical Co., Ltd.	01 Jan 2001

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01172847 (CTgov)	Phase 1	-	24	Oseltamivir (Oseltamivir)	tmdxsidsah(mdlstkomco) = oyohuxgawj hyiunqohmy (gvgslisguc, qlrcqhvjjg - spgvjtwzdj) View more	-	21 Mar 2016
				Oseltamivir+Rimantadine (Oseltamivir + Rimantadine)	tmdxsidsah(mdlstkomco) = jydtbmxmfy hyiunqohmy (gvgslisguc, vsxeaqsfxq - lytlrbybqj) View more